- Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). Leon, M.B., Kandzari, D.E., Eisenstein, E.L., Anstrom, K.J., Mauri, L., Cutlip, D.E., Nikolsky, E., O'Shaughnessy, C., Overlie, P.A., Kirtane, A.J., McLaurin, B.T., Solomon, S.L., Douglas, J.S., Popma, J.J. JACC. Cardiovasc. Interv (2009)